Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy

Area of Science:

• Health Economics
• Cardiovascular Disease Prevention
• Pharmacoeconomics

Background:

• Coronary heart disease (CHD) poses a significant economic burden on healthcare systems.
• Clinical trials like the Helsinki Heart Study (HHS) demonstrate the efficacy of lipid-lowering agents.
• Translating clinical benefits into economic terms is crucial for managed care decision-making.

Purpose of the Study:

• To determine the cost-effectiveness of gemfibrozil in preventing coronary heart disease (CHD).
• To assess the overall impact of gemfibrozil on total CHD treatment costs.
• To identify specific patient demographics that benefit most from gemfibrozil therapy.

Main Methods:

• A cost-effectiveness model was developed using HHS data and US healthcare cost information.
• The model was applied to the California Medicaid (Medi-Cal) program to estimate therapy costs and savings.
• Patient risk profiles (cholesterol, age, sex, risk factors) were used to stratify CHD event probabilities.

Main Results:

• Gemfibrozil treatment reduced the probability of acute myocardial infarction (AMI) and sudden cardiac death by 34%.
• Expected 5-year CHD care costs ranged from $242 (low-risk male) to $8084 (high-risk male) without treatment.
• Gemfibrozil therapy led to significant reductions in expected coronary event costs, ranging from $82 to $1997.

Conclusions:

• Gemfibrozil is a cost-effective intervention for preventing coronary heart disease.
• The therapy offers net expected savings for managed care programs like Medi-Cal.
• Risk-factor stratification can identify patient groups for whom gemfibrozil therapy is most beneficial.